StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Duodopa [folded into Other Neuroscience in Q1 2026] by Quarter

Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Duodopa [folded into Other Neuroscience in Q1 2026]: -15.1% in Q4 2025, down 9.3 pts from a year earlier.

Latest, Q4 2025
-15.1%
Period ended Dec 31, 2025
Change on a year earlier
-9.3 pts
-5.8% in Q4 2024
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below

Where the Q4 2025 figure comes from

“|| Duodopa | 17 | 75 | 92 | (31.6) | (10.4) | (15.1) | (14.9) | (18.6)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDuodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide reported growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 2025-15.1%-9.3 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-13.5%-6.9 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-13.7%-10.6 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-16.7%-14.0 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-5.8%-13.7 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-6.6%-14.0 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-3.1%-0.2 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-2.7%-0.5 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20237.9%+24.2 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20237.4%+20.5 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-2.9%+2.5 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-2.2%+4.5 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-16.3%-14.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-13.1%-17.0 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 2022-5.4%-13.2 ptsForm 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 2022-6.7%-10.6 ptsForm 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗

Cite this data

StockData. (2026). AbbVie Duodopa [folded into Other Neuroscience in Q1 2026] (%), quarterly Q4 2017–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/duodopa-ww-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.